Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Stock Information for Mereo BioPharma Group plc
Loading
Please wait while we load your information from QuoteMedia.